Movement Alert｜RemeGen Falls 5.33% in Regular Trading, HK Innovative Drug Sector Under Sustained Selling Pressure

Market Focus06-22

On June 22, RemeGen (09995.HK) fell 5.33% in regular trading, trading at HKD 64.35 per share, with turnover of HKD 112 million.

On the news front, the Hong Kong-listed innovative drug sector has been under sustained selling pressure since early June, with an accelerating downtrend. On the same day, the broader biotechnology sector saw widespread declines, with AKESO down 7.25%, SKB Bio down 6.45%, 3SBio down 4.37%, Innovent Bio down 4.33%, and BeiGene down 3.42%, reflecting deeply depressed sector sentiment.

Market concerns have intensified over rising expectations for a Fed rate hike and uncertainties surrounding BD (business development) overseas licensing prospects. Combined with profit-taking pressure following significant cumulative gains in the prior period, capital outflows from the innovative drug sector have persisted. The sector-wide selloff reflects macro and industry-level headwinds rather than company-specific catalysts, as multiple leading biotech names experienced comparable declines.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134016681?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 10:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134016681","market":"us","top_or_hot":-1,"title":"Movement Alert｜RemeGen Falls 5.33% in Regular Trading, HK Innovative Drug Sector Under Sustained Selling Pressure","media":"Market Focus","content":"<p><p>On June 22, RemeGen (09995.HK) fell 5.33% in regular trading, trading at HKD 64.35 per share, with turnover of HKD 112 million.</p><p>On the news front, the Hong Kong-listed innovative drug sector has been under sustained selling pressure since early June, with an accelerating downtrend. On the same day, the broader biotechnology sector saw widespread declines, with AKESO down 7.25%, SKB Bio down 6.45%, 3SBio down 4.37%, Innovent Bio down 4.33%, and BeiGene down 3.42%, reflecting deeply depressed sector sentiment.</p><p>Market concerns have intensified over rising expectations for a Fed rate hike and uncertainties surrounding BD (business development) overseas licensing prospects. Combined with profit-taking pressure following significant cumulative gains in the prior period, capital outflows from the innovative drug sector have persisted. The sector-wide selloff reflects macro and industry-level headwinds rather than company-specific catalysts, as multiple leading biotech names experienced comparable declines.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜RemeGen Falls 5.33% in Regular Trading, HK Innovative Drug Sector Under Sustained Selling Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜RemeGen Falls 5.33% in Regular Trading, HK Innovative Drug Sector Under Sustained Selling Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-22 10:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 22, RemeGen (09995.HK) fell 5.33% in regular trading, trading at HKD 64.35 per share, with turnover of HKD 112 million.</p><p>On the news front, the Hong Kong-listed innovative drug sector has been under sustained selling pressure since early June, with an accelerating downtrend. On the same day, the broader biotechnology sector saw widespread declines, with AKESO down 7.25%, SKB Bio down 6.45%, 3SBio down 4.37%, Innovent Bio down 4.33%, and BeiGene down 3.42%, reflecting deeply depressed sector sentiment.</p><p>Market concerns have intensified over rising expectations for a Fed rate hike and uncertainties surrounding BD (business development) overseas licensing prospects. Combined with profit-taking pressure following significant cumulative gains in the prior period, capital outflows from the innovative drug sector have persisted. The sector-wide selloff reflects macro and industry-level headwinds rather than company-specific catalysts, as multiple leading biotech names experienced comparable declines.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1134016681","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134016681","pubTimestamp":1782094769,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 22, RemeGen (09995.HK) fell 5.33% in regular trading, trading at HKD 64.35 per share, with turnover of HKD 112 million.On the news front, the Hong Kong-listed innovative drug sector has been...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"异动快讯|RemeGen常规交易跌5.33%香港创新药板块持续抛压","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"On June 22, RemeGen (09995.HK) fell 5.33% in regular trading, trading at HKD 64.35 per share, with turnover of HKD 112 million.On the news front, the Hong Kong-listed innovative drug sector has been under sustained selling pressure since early June, with an accelerating downtrend. On the same day, the broader biotechnology sector saw widespread declines, with AKESO down 7.25%, SKB Bio down 6.45%, 3SBio down 4.37%, Innovent Bio down 4.33%, and BeiGene down 3.42%, reflecting deeply depressed sector sentiment.Market concerns have intensified over rising expectations for a Fed rate hike and uncertainties surrounding BD (business development) overseas licensing prospects. Combined with profit-taking pressure following significant cumulative gains in the prior period, capital outflows from the innovative drug sector have persisted. The sector-wide selloff reflects macro and industry-level headwinds rather than company-specific catalysts, as multiple leading biotech names experienced comparable declines.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134016681","isCrawlerRequest":true}